Autoinflammatory & rare systemic diseases
Colchicine resistance prediction criteria from the Turkish Paediatric Autoinflammatory Diseases (TURPAID) cohort do not apply to the Juvenile Inflammatory Rheumatism (JIR) cohort: a multicentre descriptive analysis
Authors' conclusion
The TURPAID score did not effectively predict colchicine resistance in the JIR cohort.
Study context
- Population
- Genetically confirmed paediatric and adult Familial Mediterranean fever (FMF) patients treated with colchicine for ≥6 months, international JIR cohort
- Participants
- 236 participants
- Exposure
- TURPAID score for predicting colchicine resistance: Colchicine-resistant (CoR) vs colchicine-sensitive (CoS) patients
- Outcome
- Predictive value of the TURPAID score for colchicine resistance (ROC analysis)
Methodological detailsmulticentre, descriptive analysis, matched for age and sex
- Multicentre
- Descriptive analysis
- Matched for age and sex
Main finding
As reported in the abstract
Discrimination of TURPAID score for colchicine resistance (ROC)
AUC, paediatric and adult groups (poor discrimination)
0.6
Observational data: associations, not effects.
Further findings
TURPAID score ≥2 in CoS patients
- Paediatric CoS
- 89%
- Adult CoS
- 76%
Mean TURPAID score by age at onset
- Mean scores significantly higher in paediatric-onset FMF
Genetic component (1.5 points for MEFV exon 10 mutations)
- Contributed to overclassification, reducing predictive accuracy
Original publication
Colchicine resistance prediction criteria from the TURPAID cohort do not apply to the JIR cohort: a multicentre descriptive analysis. RMD Open. Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →